Incyte

INCY78

High Growth

$70.39arrow_drop_down0.97%-$0.68

High Growth

S&P500

INCY78

$70.39

arrow_drop_down0.97%-$0.68

High Growth

S&P500

Performance History

Key Stats
Open	$70.66
Prev. Close	$70.56
EPS	0.09
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	68.62	71.64
52 Week Range	50.27	84.12

Ratios







EPS	0.09

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Incyte (INCY)

Incyte Corp (INCY) is a pharmaceutical company that primarily focuses on the discovery, development, and commercialization of innovative therapies for the treatment of various diseases. The company's main areas of expertise include oncology, inflammation, and autoimmune diseases. Through its extensive research and development efforts, Incyte has successfully developed several drugs that have been approved for commercial use. One of its most notable drugs is Jakafi, which is used for the treatment of certain types of blood cancers. This drug has shown significant efficacy in clinical trials and has become a major revenue driver for the company.

Incyte Corp has a strong track record of delivering solid financial performance. The company has consistently reported revenue growth over the past few years, driven by the success of its drugs in the market. In addition, Incyte has a robust pipeline of promising drug candidates that are currently in various stages of development. This provides the company with multiple opportunities for future revenue growth. Incyte also places a strong emphasis on research and innovation, investing heavily in its R&D activities. This allows the company to stay at the forefront of scientific advancements and continuously develop new and improved therapies.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Herve Hoppenot
Headquarters: Wilmington
Employees: 2324
Exchange: NASDAQ

Keep an eye on Incyte

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Incyte's (INCY) price per share?

The current price per share for Incyte (INCY) is $70.39. The stock has seen a price change of -$0.69 recently, indicating a -0.97% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Incyte (INCY)?

For Incyte (INCY), the 52-week high is $84.12, which is 19.51% from the current price. The 52-week low is $50.27, the current price is 40.02% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Incyte (INCY) a growth stock?

Incyte (INCY) has shown an average price growth of -7.23% over the past three years. It has received a score of 63 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Incyte as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Incyte (INCY) stock price performance year to date (YTD)?

As of the latest data, Incyte (INCY) has a year-to-date price change of 7.55%. Over the past month, the stock has experienced a price change of 7.84%. Over the last three months, the change has been 9.73%. Over the past six months, the figure is 22.63%. Looking at a longer horizon, the five-year price change stands at -20.37%.

help

Is Incyte (INCY) a profitable company?

Incyte (INCY) has a net income of $597.6M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.1% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 14.96% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.7B, with a revenue growth rate of 8.87%, providing insight into the company's sales performance and growth. The gross profit is $3.44B. Operating income is noted at $620.52M. Furthermore, the EBITDA is $904.74M.

help

What is the market capitalization of Incyte (INCY)?

Incyte (INCY) has a market capitalization of $13.56B. The average daily trading volume is 70.33, indicating the stock's liquidity and investor engagement.